Compare ARLP & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | CORT |
|---|---|---|
| Founded | 1971 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 1999 | N/A |
| Metric | ARLP | CORT |
|---|---|---|
| Price | $24.53 | $38.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $29.50 | ★ $114.20 |
| AVG Volume (30 Days) | 444.1K | ★ 2.1M |
| Earning Date | 02-02-2026 | 02-25-2026 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.42 | 0.87 |
| Revenue | ★ $2,194,811,000.00 | $741,172,000.00 |
| Revenue This Year | $6.11 | $23.09 |
| Revenue Next Year | $3.31 | $29.62 |
| P/E Ratio | ★ $10.13 | $43.92 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $22.20 | $32.99 |
| 52 Week High | $28.50 | $117.33 |
| Indicator | ARLP | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 36.13 |
| Support Level | $23.80 | $38.10 |
| Resistance Level | $25.49 | $41.36 |
| Average True Range (ATR) | 0.57 | 2.35 |
| MACD | -0.06 | 1.19 |
| Stochastic Oscillator | 8.42 | 39.46 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties has included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.